Clinical trials: Epithelial Neoplasms, Malignant
Non-Small Cell Lung Cancer
Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.
This phase I, first-in-human dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary…
- Trial name
- NCT03130881
- Testing
- PLB1003
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Early-Stage Breast Carcinoma
Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer
Sentinel node biopsy is a well established tool for axillary staging in early breast cancer. So far the impact of a preoperative lymph node scintigraphy is unclear.
- Trial name
- NCT02481128
- Testing
- without preoperative access to lymphoscintigraphy findings
- Where
- 23 sites in Germany, Switzerland
- Volunteers
- 1,198 people
- Sponsor
- Kliniken Essen-Mitte
Carcinoma, Non-small-Cell Lung
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in…
- Trial name
- PALOMA-2 (NCT05498428)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 110 sites in United States, Brazil and 10 more
- Volunteers
- 520 people
- Sponsor
- Janssen Research & Development, LLC
HCC, Hepatitis B Virus Related Hepatocellular Carcinoma
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
- Conditions
- HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT06617000
- Testing
- SCG101
- Where
- 7 sites in China
- Volunteers
- 38 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Glioblastoma
Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium?
Rationale: Visualization of tumor spread is of crucial importance when treating patients suffering from glioblastoma (GBM) as the success of tumor resection depends strongly on the extent of tumor infiltration.
- Trial name
- NCT05656300
- Testing
- MRI scan using USPIO particles
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Actinic Keratosis, Acne/Rosacea
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders
- Conditions
- Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea
- Trial name
- NCT02759900
- Testing
- Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Skin Center Dermatology Group
Lung Diseases, Mesothelioma
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
The goal of this clinical research study is to compare Progel® (a type of surgical sealant that is made from human blood products) to the standard of care (talcum powder) to learn if one method is better than the other for…
- Trial name
- NCT02511600
- Testing
- Progel Sealant, Talcum Powder, Pain Questionnaire
- Sponsor
- M.D. Anderson Cancer Center
Liver Tumors, Hepatocellular Carcinoma
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
This is an interdisciplinary study that falls into the Humanitarian Use Device category. There are no hypotheses to be tested in this treatment protocol. The study has the following objectives: 1.
- Conditions
- Liver Tumors, Hepatocellular Carcinoma, Hepatoma, Neoplasms
- Trial name
- NCT00877136
- Testing
- TheraSphere®
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Joseph Hospital of Orange
Esophageal Squamous Cell Carcinoma
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
- Trial name
- ESCC (NCT06601309)
- Testing
- Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Medical University Union Hospital
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic…
- Trial name
- ALKAZAR (NCT06765109)
- Testing
- Neladalkib (NVL-655), Alectinib
- Where
- 159 sites in United States, Argentina and 27 more
- Volunteers
- 450 people
- Sponsor
- Nuvalent Inc.
Nasopharyngeal Carcinoma
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
- Trial name
- NCT04227509
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
SIRT and Peri-immunotherapy : a New Concept
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC…
- Trial name
- IMSIRT (NCT06971237)
- Testing
- Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization, Atezolizumab ± Bevacizumab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma
A retrospective observational study to evaluate immunohistochemical expression of Inhibin Beta A (INHBA) in 60 cases of Colorectal Carcinoma, and compare levels of its expression to different clinicopathological criteria.
- Trial name
- NCT05794737
- Testing
- Immunohistochemical staining
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Squamous Cell Carcinoma of the Head and Neck
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04672772
- Testing
- Cetuximab, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 531 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
This pilot clinical trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) works in imaging lymph nodes in patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes…
- Conditions
- Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7
- Trial name
- NCT03280277
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
This clinical trial is studying patient, physician, and nurse factors associated with entry onto clinical trials and finishing treatment in patients with primary or recurrent uterine, endometrial, or cervical cancer.
- Conditions
- Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Corpus Sarcoma, Stage I Uterine Corpus Cancer
- Trial name
- NCT01098630
- Testing
- Medical Chart Review, Questionnaire Administration
- Where
- 167 sites in United States
- Volunteers
- 778 people
- Sponsor
- Gynecologic Oncology Group
Unresectable Hepatocellular Carcinoma
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
- Trial name
- ABH-uHCC (NCT07806292)
- Testing
- anlotinib combined with benmelstobart and HAIC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-small Cell Lung Cancer, Quality of Life
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
- Conditions
- Non-small Cell Lung Cancer, Quality of Life, Brain Metastases, Venous Thromboembolism
- Trial name
- NCT03870464
- Testing
- CT-scans extended, MRI scan of the brain, Prospective registration of irAEs
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- University of Southern Denmark
Hepatocellular Carcinoma (HCC)
Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab
Increased pyruvate-to-lactate conversion is a hallmark of HCC metabolism. In parallel, activation of pro-inflammatory immune cells triggers a metabolic switch towards anaerobic glycolysis.
- Trial name
- NCT06605664
- Testing
- Hyperpolarized 13C pyruvate MRI
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Squamous Cell Carcinoma
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The investigators hypothesize that inhibition of angiogenesis and PD-1 will be more effective than inhibition of PD-1 alone. The first step in pursuing proof of this hypothesis is to establish the safety and feasibility of…
- Trial name
- NCT03650764
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.